Zurcher Kantonalbank Zurich Cantonalbank Has $302,000 Stake in Xencor, Inc. (NASDAQ:XNCR)

Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Xencor, Inc. (NASDAQ:XNCR) by 13.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 14,215 shares of the biopharmaceutical company’s stock after buying an additional 1,640 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Xencor were worth $302,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. BluePath Capital Management LLC bought a new stake in Xencor during the third quarter worth approximately $31,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Xencor by 95.5% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,548 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 756 shares during the period. Allworth Financial LP boosted its holdings in shares of Xencor by 29,487.5% during the 4th quarter. Allworth Financial LP now owns 2,367 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 2,359 shares during the period. Exchange Traded Concepts LLC grew its stake in Xencor by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 6,776 shares of the biopharmaceutical company’s stock valued at $144,000 after buying an additional 1,718 shares during the last quarter. Finally, Hsbc Holdings PLC bought a new position in Xencor in the 3rd quarter worth $213,000.

Xencor Trading Up 2.0 %

Shares of XNCR stock opened at $24.11 on Monday. The firm has a fifty day moving average of $21.88 and a 200-day moving average of $20.50. The stock has a market cap of $1.49 billion, a price-to-earnings ratio of -11.48 and a beta of 0.77. Xencor, Inc. has a 52-week low of $16.49 and a 52-week high of $28.96. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.36 and a current ratio of 7.36.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.36 by ($0.67). The business had revenue of $44.70 million during the quarter, compared to analyst estimates of $77.63 million. Xencor had a negative return on equity of 18.67% and a negative net margin of 74.90%. The business’s revenue for the quarter was up 106.9% on a year-over-year basis. During the same period last year, the company earned ($0.20) EPS. On average, equities research analysts forecast that Xencor, Inc. will post -3.25 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have issued reports on XNCR. BTIG Research decreased their price target on shares of Xencor from $56.00 to $38.00 and set a “buy” rating for the company in a report on Tuesday, April 16th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $32.00 price target on shares of Xencor in a research report on Wednesday, February 28th. Wedbush reduced their price objective on Xencor from $36.00 to $34.00 and set an “outperform” rating for the company in a research report on Wednesday, February 28th. BMO Capital Markets lowered their price objective on shares of Xencor from $38.00 to $34.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 28th. Finally, Mizuho cut their target price on shares of Xencor from $59.00 to $50.00 and set a “buy” rating for the company in a research note on Monday, January 22nd. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $36.00.

Insider Transactions at Xencor

In related news, VP John R. Desjarlais sold 54,108 shares of the business’s stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $19.38, for a total value of $1,048,613.04. Following the sale, the vice president now owns 161,675 shares of the company’s stock, valued at approximately $3,133,261.50. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other Xencor news, VP John R. Desjarlais sold 54,108 shares of the company’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $19.38, for a total transaction of $1,048,613.04. Following the sale, the vice president now directly owns 161,675 shares of the company’s stock, valued at $3,133,261.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Kurt A. Gustafson sold 14,000 shares of the stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $23.18, for a total value of $324,520.00. Following the sale, the director now owns 6,007 shares in the company, valued at $139,242.26. The disclosure for this sale can be found here. In the last ninety days, insiders sold 101,351 shares of company stock valued at $2,152,417. Corporate insiders own 4.97% of the company’s stock.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.